Top High Growth Tech Stocks To Watch In September 2024

Over the last 7 days, the market has risen 4.2%, driven by gains of 7.4% in the Information Technology sector. The market is up 24% over the last 12 months, with earnings forecast to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks that align with these trends can be crucial for investors looking to capitalize on this momentum.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.39%	43.54%	★★★★★★
Super Micro Computer	20.49%	27.13%	★★★★★★
Sarepta Therapeutics	23.58%	44.12%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
Ardelyx	27.44%	65.92%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Travere Therapeutics	26.68%	68.80%	★★★★★★
Ascendis Pharma	39.71%	68.43%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Adeia (NasdaqGS:ADEA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Adeia Inc., along with its subsidiaries, operates as a media and semiconductor intellectual property licensing company across the United States, Canada, Asia, Europe, the Middle East, and internationally with a market cap of approximately $1.30 billion.

Operations: Adeia Inc. generates revenue primarily through intellectual property licensing, with the IP Licensing segment contributing $359.02 million. The company operates in various regions including the United States, Canada, Asia, Europe, and the Middle East.

Adeia's revenue is forecast to grow at 9.9% annually, outpacing the US market's 8.8%. However, recent earnings growth has been negative at -51.9%, contrasting with the software industry's 23.9% average growth. The company's R&D expenses are significant, reflecting its commitment to innovation; they recently reported $170.76 million in sales for six months ending June 30, 2024, down from $200.52 million a year ago while net income improved to $8.38 million from $1.42 million in Q2 YoY comparison. Adeia's strategic partnerships and licensing agreements with companies like Hamamatsu Photonics and Liberty Global underscore its influence in semiconductor IP and media technology sectors respectively; these collaborations enhance their technological footprint globally. With an expected annual profit growth rate of 44.86%, significantly higher than the US market’s forecasted 15%, Adeia is poised for substantial earnings improvement despite current financial challenges such as lower profit margins (12.9%) compared to last year (24%).

• Navigate through the intricacies of Adeia with our comprehensive health report here.

• Gain insights into Adeia's historical performance by reviewing our past performance report.

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs worldwide, with a market cap of $1.80 billion.

Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $338.93 million. The company focuses on addressing significant unmet medical needs in patients with debilitating diseases.

Kiniksa Pharmaceuticals International is poised for significant growth, with revenue forecasted to increase by 17.8% annually, outpacing the broader US market's 8.8%. Despite a net loss of $3.91 million in Q2 2024 compared to a net income of $14.97 million the previous year, their R&D expenses reflect a strong commitment to innovation, particularly with ongoing trials like the Phase 2b study for abiprubart in Sjögren’s Disease. The company also revised its revenue guidance upwards for 2024 to between $405 million and $415 million from an earlier range of $370 million to $390 million, indicating robust future prospects despite current financial challenges.

• Take a closer look at Kiniksa Pharmaceuticals International's potential here in our health report.

• Explore historical data to track Kiniksa Pharmaceuticals International's performance over time in our Past section.

Teradata (NYSE:TDC)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Teradata Corporation, with a market cap of $2.74 billion, provides a connected multi-cloud data platform for enterprise analytics through its subsidiaries.

Operations: The company generates revenue from three primary regions: Americas ($1.06 billion), Asia Pacific and Japan (APJ) ($259 million), and Europe, Middle East, and Africa (EMEA) ($481 million). The focus is on providing a connected multi-cloud data platform for enterprise analytics.

Teradata's recent integration with DataRobot AI Platform and Google Cloud's Vertex AI highlights its commitment to advancing scalable AI solutions. Despite a slight revenue dip to $436 million from $462 million last year, net income surged to $37 million, reflecting operational efficiency. The company repurchased 1.13 million shares for $40.14 million in Q2 2024, emphasizing shareholder value. With earnings projected to grow at 29.7% annually and robust R&D investments, Teradata is poised for significant advancements in the tech sector.

• Click here to discover the nuances of Teradata with our detailed analytical health report.

• Understand Teradata's track record by examining our Past report.

Next Steps

• Delve into our full catalog of 251 US High Growth Tech and AI Stocks here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com